GW Henssler & Associates Ltd. raised its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 4.1% during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 167,056 shares of the biopharmaceutical company’s stock after buying an additional 6,547 shares during the quarter. Gilead Sciences comprises 1.4% of GW Henssler & Associates Ltd.’s portfolio, making the stock its 24th largest position. GW Henssler & Associates Ltd.’s holdings in Gilead Sciences were worth $13,535,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors have also recently made changes to their positions in GILD. Lowe Brockenbrough & Co. Inc. raised its stake in Gilead Sciences by 0.3% during the first quarter. Lowe Brockenbrough & Co. Inc. now owns 19,455 shares of the biopharmaceutical company’s stock valued at $1,321,000 after buying an additional 60 shares in the last quarter. Bank of Nova Scotia raised its stake in Gilead Sciences by 344.4% during the first quarter. Bank of Nova Scotia now owns 306,114 shares of the biopharmaceutical company’s stock valued at $20,791,000 after buying an additional 237,236 shares in the last quarter. Polianta Ltd raised its stake in Gilead Sciences by 23.4% during the second quarter. Polianta Ltd now owns 17,400 shares of the biopharmaceutical company’s stock valued at $1,231,000 after buying an additional 3,300 shares in the last quarter. Private Asset Management Inc. raised its position in shares of Gilead Sciences by 3.0% during the 2nd quarter. Private Asset Management Inc. now owns 118,850 shares of the biopharmaceutical company’s stock worth $8,412,000 after purchasing an additional 3,440 shares during the period. Finally, DnB Asset Management AS raised its position in shares of Gilead Sciences by 17.0% during the 2nd quarter. DnB Asset Management AS now owns 250,382 shares of the biopharmaceutical company’s stock worth $17,722,000 after purchasing an additional 36,400 shares during the period. Hedge funds and other institutional investors own 76.11% of the company’s stock.
Shares of Gilead Sciences, Inc. (GILD) traded down $1.76 during mid-day trading on Friday, reaching $81.73. The company had a trading volume of 9,356,342 shares, compared to its average volume of 8,410,000. Gilead Sciences, Inc. has a 1-year low of $63.76 and a 1-year high of $89.54. The company has a market cap of $106,730.00, a price-to-earnings ratio of 9.30, a price-to-earnings-growth ratio of -1.85 and a beta of 1.22. The company has a debt-to-equity ratio of 1.10, a current ratio of 3.68 and a quick ratio of 3.56.
Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $2.27 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.13 by $0.14. The business had revenue of $6.51 billion during the quarter, compared to analyst estimates of $6.40 billion. Gilead Sciences had a return on equity of 57.15% and a net margin of 42.22%. The business’s revenue for the quarter was down 13.2% compared to the same quarter last year. During the same period in the prior year, the company posted $2.75 EPS. sell-side analysts forecast that Gilead Sciences, Inc. will post 8.53 EPS for the current fiscal year.
A number of analysts have recently weighed in on the company. Vetr cut Gilead Sciences from a “buy” rating to a “hold” rating and set a $91.25 price target on the stock. in a research report on Monday. Citigroup upgraded Gilead Sciences from a “neutral” rating to a “buy” rating and dropped their price target for the stock from $88.80 to $76.00 in a research report on Tuesday. Morgan Stanley reiterated an “equal weight” rating and set a $83.00 price target (up from $77.00) on shares of Gilead Sciences in a research report on Friday, October 6th. Barclays reiterated an “overweight” rating and set a $90.00 price target on shares of Gilead Sciences in a research report on Wednesday, October 11th. Finally, Leerink Swann increased their price target on Gilead Sciences from $87.00 to $89.00 and gave the stock a “market perform” rating in a research report on Thursday, October 5th. One analyst has rated the stock with a sell rating, thirteen have given a hold rating and eighteen have issued a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus price target of $85.58.
In other Gilead Sciences news, EVP James R. Meyers sold 100,000 shares of the stock in a transaction on Tuesday, January 16th. The stock was sold at an average price of $80.24, for a total transaction of $8,024,000.00. Following the completion of the transaction, the executive vice president now directly owns 102,715 shares of the company’s stock, valued at approximately $8,241,851.60. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider John F. Milligan sold 220,000 shares of the stock in a transaction on Monday, November 13th. The shares were sold at an average price of $72.88, for a total value of $16,033,600.00. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 503,333 shares of company stock valued at $37,834,758. 1.30% of the stock is currently owned by corporate insiders.
TRADEMARK VIOLATION NOTICE: “Gilead Sciences, Inc. (NASDAQ:GILD) Shares Bought by GW Henssler & Associates Ltd.” was posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this piece on another site, it was illegally stolen and reposted in violation of US & international trademark and copyright laws. The original version of this piece can be read at https://www.dispatchtribunal.com/2018/02/02/gw-henssler-associates-ltd-buys-6547-shares-of-gilead-sciences-inc-gild.html.
Gilead Sciences Company Profile
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.